This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene & HMHB Hawaii Expand Partnership for Maternal Care
by Zacks Equity Research
CNC's Ohana Health Plan and HMHB Hawaii expand maternal care, enhancing support for mothers and babies through strategic investment and community partnerships.
Option Care Health, Inc. (OPCH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Option Care (OPCH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Reasons Growth Investors Will Love Option Care (OPCH)
by Zacks Equity Research
Option Care (OPCH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
OPCH vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
OPCH vs. CHE: Which Stock Is the Better Value Option?
Centene's Meridian Unit Secures a D-SNP Contract in Illinois
by Zacks Equity Research
CNC's Meridian Health Plan wins a D-SNP contract in Illinois, expanding enhanced managed care for Medicare-Medicaid-eligible individuals. The deal is likely to boost Centene's foothold and membership base in the state.
Teladoc Boosts Weight Care Access With LillyDirect, Aids Growth
by Zacks Equity Research
TDOC expands weight care access with LillyDirect, boosting growth by offering affordable GLP-1 medications like Zepbound, enhancing patient outcomes and engagement.
Here's Why Ensign Group Can be a Smart Addition to Your Portfolio
by Zacks Equity Research
ENSG remains well-poised for growth on growing service revenues, an expanding healthcare portfolio and sufficient cash balance.
Here is Why Growth Investors Should Buy Option Care (OPCH) Now
by Zacks Equity Research
Option Care (OPCH) could produce exceptional returns because of its solid growth attributes.
3 Healthcare Stocks With Strong EPS Growth Potential to Buy in 2025
by Kaibalya Pravo Dey
GILD, OPCH and AVAH demonstrate resilience with impressive earnings surprise history.
3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,
by Shaun Pruitt
These highly ranked medical stocks have the value and essential services that investors may be looking for as tariff concerns and geopolitical tensions have started to rattle markets.
Teladoc Health Enhances Prism Platform for Better Virtual Care
by Zacks Equity Research
TDOC upgrades its Prism platform with AI-powered tools, improved referrals and data integration, enhancing care coordination to bolster its member base.
Earnings Estimates Rising for Option Care (OPCH): Will It Gain?
by Zacks Equity Research
Option Care (OPCH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
OPCH or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OPCH vs. CHE: Which Stock Is the Better Value Option?
Best Momentum Stocks to Buy for March 4th
by Zacks Equity Research
OPCH and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 4, 2025.
Option Care Health, Inc. (OPCH) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Option Care (OPCH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
New Strong Buy Stocks for March 4th
by Zacks Equity Research
OPCH, LMAT, C, FFIN and IBCP have been added to the Zacks Rank #1 (Strong Buy) List on March 4, 2025.
After Golden Cross, Option Care (OPCH)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Option Care (OPCH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 6.06% and 1.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
LifeStance Health Group (LFST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
LifeStance Health (LFST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Option Care (OPCH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Option Care (OPCH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks Industry Outlook Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare
by Zacks Equity Research
Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare have been highlighted in this Industry Outlook article.
4 Stocks to Monitor in a Dynamic Outpatient Home Health Industry
by Debanjana Dey
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, OPCH and ADUS are well-poised to gain.
Option Care (OPCH) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 32.26% and 4.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
OPCH vs. ASTH: Which Stock Is the Better Value Option?
by Zacks Equity Research
OPCH vs. ASTH: Which Stock Is the Better Value Option?